Chemical Probes logo
Baricitinib | Inhibitor of JAK1, JAK2
RATINGS:
Cellular Use: (1 reviews)

In Model Organisms: (1 reviews)
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download

Probe Summary

More...

Targets Biochemical/Biophysical Potency Cellular Potency
JAK1
  • IC 50:5.9 nM
    JAK2
    • IC 50:5.7 nM
    • IC 50:44 nM
    • IC 50:128 nM
    • IC 50:20 nM
    • IC 50:40 nM
    Inhibitor
    up to 100 nM

    Selectivity

    In Vitro Selectivity Assessment

    Potency: IC50 - Tyk2 53 nM, JAK3 560 nM, AAK1 17.2 nM, BIKE 39.8 nM, GAK134.4 nM, MPSK1 68.5 nM

    Potency Assay Off-Target:
    TR-FRET, ITC
    Selectivity Assessment Description:
    JAK3 IC50 ~ 560 nM, ~10-fold selectivity against Tyk2 (IC50 = 53 nM), c-Met (IC50 > 10,000 nM) ...

    Potency
    Cellular
    In Vitro

    JAK1

    Mode of Action: Inhibitor

    Structure-Activity-Relationship data available? No

    DOI Reference: 10.4049/jimmunol.0902819

    JAK2

    Mode of Action: Inhibitor

    Structure-Activity-Relationship data available? No

    DOI Reference: 10.4049/jimmunol.0902819

    In Vivo Validations

    Mouse, Rat
    Dose: 1, 3, 10 mg/Kg
    Route of delivery: Oral

    DOI Reference: 10.4049/jimmunol.0902819

    Negative Control Compounds

    INCB027753
    INCB029843

    Orthogonal Probes def

    Ruxolitinib
    Filgotinib

    Chemical Information

    Molecular Formula C16H17N7O2S
    SMILEs CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
    InChI InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
    Molecular weight 371.12 Da
    AlogP 1.09568
    HBond acceptors 9
    HBond donors 1
    Atoms 43

    References

    Publications

    Cross References

    Vendors

    Note: This is not an exhaustive list and does not indicate endorsement by the portal.

    Expert Reviews

    by SERP
    (on 15 Apr 2025)
    Cellular Use Rating
    In Model Organisms
    Baricitinib (alternatively named INCB28050, LY3009104) is an FDA-approved drug and a potent inhibitor of JAK1/2 with a decent in vivo profile. Baricitinib, however, is insufficiently profiled for use as...
    Note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars. Read more about our evaluation criteria